3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
350
Polycystic Ovary Syndrome
38
Endometrial Neoplasms
22
Neoplasm Metastasis
21
Ovarian Neoplasms
16
Neoplasms
11
Infertility
11
Fallopian Tube Neoplasms
8
Advanced Breast Cancer
8
Triple Negative Breast Neoplasms
7
Carcinoma, Intraductal, Noninfiltrating
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Recurrence
6
Osteoporosis
6
Carcinoma, Lobular
6
Breast Diseases
6
Breast Carcinoma In Situ
6
Prostatic Neoplasms
5
Leiomyoma
4
Infertility, Female
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Neoplasms, Hormone-Dependent
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Interventions
Paclitaxel
24
Hyperthermic Intraperitoneal Chemotherapy
24
Cisplatin
22
Oxaliplatin
17
Carboplatin
17
Fluorouracil
13
Cytoreduction Surgical Procedures
13
Bevacizumab
10
Mitomycin
9
Leucovorin
8
Doxorubicin
8
Docetaxel
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Surgical Procedures, Operative
4
Blood Specimen Collection
4
Albumin-Bound Paclitaxel
4
sodium thiosulfate
3
liposomal doxorubicin
3
catumaxomab
3
Taxes
3
Neoadjuvant Therapy
3
Drug Therapy
3
tremelimumab
2
relacorilant
2
pembrolizumab
2
olaparib
2
nintedanib
2
epothilone B
2
Topotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Peritoneal Neoplasms
×
Letrozole
×
Clear all
NCT04111978
2025-09-29
MATAO
Swiss GO Trial Group
Phase 3
Recruiting
540 enrolled